Breaking Bottlenecks in Life Sciences R&D with AI Innovation - with Aziz Nazha of Incyte Pharmaceuticals

2026-04-16 · Source: The AI in Business Podcast · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Health & Medical Research, Artificial Intelligence & Machine Learning · Depth: Intermediate, extended

Summary

Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, discusses the challenges life sciences organizations face in translating advanced AI capabilities into measurable business value for drug discovery and development. He identifies four core barriers: cultural readiness, talent gaps, fragmented data infrastructure, and unrealistic expectations. Nazha emphasizes that the issue is not the technology itself, but rather the organizational and cultural factors hindering its effective implementation. He advocates for significant investment in upskilling and reskilling the workforce, developing industry-specific AI educational content, and redesigning existing R&D workflows to better integrate AI. The goal is to shorten scientific cycles and improve success rates, moving from a 5-15% success rate to potentially 30%, rather than expecting a complete overhaul to 100% success.

Key takeaway

For Directors of AI/ML and Research Scientists in life sciences aiming to accelerate drug discovery, prioritize foundational organizational shifts over technology acquisition. Your teams need targeted, job-specific AI education and redesigned workflows to truly benefit from AI. Expect incremental gains in efficiency and success rates, like improving drug success from 15% to 30%, rather than a complete transformation, to set realistic expectations and drive sustained adoption.

Key insights

Effective AI adoption in life sciences hinges on cultural readiness, talent development, robust infrastructure, and realistic expectations.

Principles

• AI's impact is limited by organizational readiness, not technology.
• Existing workflows must be redesigned for AI integration.
• Education must be job-specific and industry-relevant.

Method

To integrate AI, focus on upskilling teams with industry-specific content, ensure data and compute infrastructure are ready, and redesign workflows to accommodate AI-driven efficiencies, rather than forcing AI into outdated processes.

In practice

• Develop internal AI educational seminars and office hours.
• Redesign R&D workflows to optimize for AI integration.
• Prioritize projects with clear ROI and executive sponsorship.

Topics

• AI Adoption Challenges
• Life Sciences R&D
• Drug Discovery
• Organizational Culture
• Talent Development

Best for: Director of AI/ML, Research Scientist, Consultant

Related on AIssential

• Meta Pivots From Open Weights, Big Pharma Bets On AI, Regulatory Patchwork, Simulating Human Cohorts — AI-native teams, advanced models, and AI-driven drug discovery are reshaping industries, while regulatory landscapes become increasingly complex.
• Strategy Summit 2026: Why AI Means Radical Change — Organizations must embrace radical AI-driven transformation, requiring a baseline understanding across all employees and integrated data platforms.
• AI Ascent 2026 — Demis Hassabis envisions AI as the most profound technology, capable of solving intelligence and subsequently all other major scientific and societal challenges.
• We spent 2 hours working in the future — Advanced AIs accelerate execution, shifting human bottlenecks to ideation, organization, and serial feedback loops.
• Top 10: AI Consulting Firms for Pharma and Life Sciences — AI consulting firms are crucial for scaling AI in pharma, moving from pilots to compliant, enterprise-wide integration.
• From Overwhelm to Working AI in Pharma and Life Sciences - with Art Shectman of Elephant Ventures — In highly regulated pharma, prioritize small, agreed-upon workflow slices for rapid, contained AI deployment to build momentum and achieve near-term ROI.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI in Business Podcast.